COST-EFFECTIVENESS AND BUDGET IMPACT ANALYSIS OF UPADACITINIB FOR THE TREATMENT OF MODERATE-TO-SEVERE ACTIVE CROHN'S DISEASE IN GREECE

被引：0
|
作者：
Vellopoulou, K. [1 ]
Lioliou, K. [1 ]
Papantoniou, P. [2 ]
Kotsis, I [2 ]
机构：
[1] Econcare LP, Athens, Greece
[2] AbbVie Hellas, Athens, Greece
来源：
VALUE IN HEALTH | 2024年 / 27卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE94
引用
收藏
页码：S72 / S72
页数：1
相关论文
共 50 条
  • [1] Cost-Effectiveness of Vedolizumab in the Treatment of Moderate-to-Severe Crohn's Disease in China
    Zhou, Ting
    Sheng, Yanan
    Guan, Haijing
    ADVANCES IN THERAPY, 2021, 38 (08) : 4233 - 4245
  • [2] Cost-Effectiveness of Vedolizumab in the Treatment of Moderate-to-Severe Crohn’s Disease in China
    Ting Zhou
    Yanan Sheng
    Haijing Guan
    Advances in Therapy, 2021, 38 : 4233 - 4245
  • [3] Upadacitinib for the treatment of moderate-to-severe Crohn's disease
    Hanzel, Jurij
    Ma, Christopher
    Jairath, Vipul
    IMMUNOTHERAPY, 2024, 16 (06) : 345 - 357
  • [4] COST-EFFECTIVENESS ANALYSIS OF BIOSIMILARS BASED TREATMENT SEQUENCES FOR MODERATE-TO-SEVERE CROHN DISEASE IN SPAIN
    Fernandez Santos, J. M.
    Monte Boquet, E.
    Borras Blasco, J.
    Romero de la Cruz, E.
    Gonzalez Galan, R.
    Singh, M. K.
    Sharma, V
    Merino-Bohorquez, V
    VALUE IN HEALTH, 2022, 25 (07) : S362 - S362
  • [5] Evaluating the pharmacokinetics of upadacitinib for the treatment of moderate-to-severe Crohn's disease
    Faggiani, Ilaria
    D'Amico, Ferdinando
    Bernardi, Francesca
    Bencardino, Sarah
    Allocca, Mariangela
    Furfaro, Federica
    Parigi, Tommaso Lorenzo
    Zilli, Alessandra
    Fiorino, Gionata
    Peyrin-Biroulet, Laurent
    Danese, Silvio
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2024, 20 (05) : 297 - 305
  • [6] Cost-effectiveness and budget impact analysis of infliximab and its biosimilar in patients with refractory moderate-to-severe Crohn's disease using real world evidence in Thailand
    Phisalprapa, Pochamana
    Kositamongkol, Chayanis
    Limsrivilai, Julajak
    Aniwan, Satimai
    Charatcharoenwitthaya, Phunchai
    Pisespongsa, Pises
    Kitiyakara, Taya
    Treepongkaruna, Suporn
    Chaiyakunapruk, Nathorn
    JOURNAL OF MEDICAL ECONOMICS, 2020, 23 (11) : 1302 - 1310
  • [7] TREATMENT OF MODERATE-TO-SEVERE ACTIVE PSORIATIC ARTHRITIS: COST-EFFECTIVENESS ANALYSIS AND BUDGET IMPACT ANALYSIS OF BIOLOGICS AND TARGETED THERAPIES APPROVED IN THE RUSSIAN FEDERATION
    Rudakova, A.
    Tolkacheva, D.
    Sokolova, V
    VALUE IN HEALTH, 2022, 25 (01) : S117 - S118
  • [8] Cost-effectiveness of treatment for moderate-to-severe psoriasis
    Hankin, CS
    Feldman, SR
    Pearce, D
    VALUE IN HEALTH, 2004, 7 (06) : 654 - 654
  • [9] Cost-effectiveness analysis of memantine for moderate-to-severe Alzheimer's disease in the Netherlands
    Hoogveldt, Bart
    Rive, Benoit
    Severens, Johan
    Maman, Khaled
    Guilhaume, Chantal
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2011, 7 : 313 - 317
  • [10] COST-EFFECTIVENESS ANALYSIS OF TOFACITINIB FOR THE TREATMENT OF MODERATE TO SEVERE ACTIVE ULCERATIVE COLITIS IN GREECE
    Vellopoulou, K.
    Stefanou, G.
    Tzanetakos, C.
    Boubouchairopoulou, N.
    Nakou, M.
    Kourlaba, G.
    VALUE IN HEALTH, 2019, 22 : S619 - S620
12345